Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Bon Health Tirzepatide Review: Cost, the Annual-Prepay Catch & Honest Verdict (2026)

An honest 2026 review of Bon Health tirzepatide — a $170/month rate that requires a full year up front, and 'Coming Soon' brand-name pages.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Sesame Care

Established national telehealth marketplace with the widest real brand-name access — Zepbound, Mounjaro, Wegovy, Ozempic, and oral Rybelsus — though brand meds carry a separate platform subscription.

Zepbound from $299/mo + $99/mo subscription

Check Sesame Care availability

Bon Health: it names both 503A and 503B compounding pharmacies and lists brand-name Wegovy, Ozempic, Zepbound, and Mounjaro right alongside its compounded tiers. Though, every one of those brand-name CTAs actually reads "Coming Soon" and routes back to the compounded product — worth knowing before assuming brand access is really available today. Every fact here comes from the company's own published program.

What Bon Health is

Bon Health is a physician-led GLP-1 weight-loss telehealth service, selling compounded semaglutide and tirzepatide on commitment tiers. It uses both 503A and 503B compounding pharmacies, and is licensed in all 50 states, with 24/7 physician support included free with every order.

§ Bon Health — The Prepay Catch and the 'Coming Soon' Brand Pages

ItemDetail
Tirzepatide, annual prepay$170/mo
Semaglutide, monthly billed$230/mo
Brand-name pagesWegovy/Ozempic/Zepbound/Mounjaro marked "Coming Soon,"
Terms pageReturned a 404 at last check
Verified: named pharmacies, $170/mo annual rate. Brand pages marked Coming Soon, terms page 404.

What Bon Health costs

The advertised $170/month rate for tirzepatide requires a full year paid up front. Billed monthly instead, the rate for compounded semaglutide is $230 — nearly double the annual-prepay figure. Read the specific commitment tier before assuming $170 is what you'll pay.

The 'Coming Soon' brand pages

This review that Bon Health's site references Wegovy, Ozempic, Zepbound, and Mounjaro by name. Though, every brand-name product page is marketed but not actually purchasable — each CTA reads "Coming Soon" and redirects back to the compounded version. If brand-name access is what draws you to the site, confirm directly that it's actually available before assuming the brand names on the page mean brand access today.

Coverage claims that don't fully agree

A site badge claims coverage in all 50 states, while the weight-loss program page itself says availability "varies by state" — a minor internal inconsistency worth clarifying directly. The terms page also returned a 404 at the time of review, making the refund mechanics behind the prepaid 3-, 6-, and 12-month tiers unreadable; confirm those terms are now live before prepaying a year.

The brand-vs-compounded question

Bon Health currently dispenses compounded tirzepatide only in practice, despite listing brand names on the site — those brand pages are marked "Coming Soon,". Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Bon Health's real strengths: named 503A and 503B pharmacies, $0 membership fee, and 24/7 physician support included free. The trade-offs: the advertised $170/month rate requires a full year prepaid, with the monthly-billed rate nearly double at $230; the brand-name pages are marketing rather than live products; coverage claims are internally inconsistent between a 50-state badge and a "varies by state" disclaimer; and the terms page returned a 404 at last check, leaving refund mechanics unreadable. As with any GLP-1 program, and especially one asking for a year prepaid, confirm the refund terms are live and readable before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Bon Health's named pharmacies and free 24/7 support are genuine positives, but the $170 headline rate requires a full year prepaid, the advertised brand-name access isn't actually live yet, and the terms page returning a 404 at last check makes the refund mechanics behind that prepayment unreadable — confirm all three directly before committing a year's payment. For a provider with a genuinely working brand-name pathway today, compare it against Better U Care or RxSpan MD. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

How much does tirzepatide cost through Bon Health?

$170/month — but that rate requires a full year paid up front. Billed monthly, semaglutide runs $230.

Can I get brand-name Zepbound through Bon Health?

The site lists Wegovy, Ozempic, Zepbound, and Mounjaro, but every brand-name CTA reads "Coming Soon" and redirects to the compounded product — brand access isn't actually live yet.

Does Bon Health name its compounding pharmacy?

Yes — both 503A and 503B compounding pharmacies are used.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.